Ferroelectric materials toward next-generation electromechanical technologies - Science | AAAS

One of the major bottlenecks in AI computing is the power consumption associated with the memory. Within the EU and Business Finland funded project FAMES, VTT has developed a pilot-line platform for a new type of hyper efficient memory technology. Recent results now show that, by tuning the switching oxide, the fabrication can be made relatively invariant to process fluctuations across an entire wafer, enabling state-of-the-art wafer uniformity. Contemporary memory solutions are all charge-based, and for high frequency computations with large data sets, such as AI computing, they are exceptionally ill-fitted: They are too slow and fail after only a few tens of thousands of reprogramming cycles (NAND-flash), They are volatile such that they lose their memory state within microseconds, making them extremely power hungry (DRAM), orThey have a large footprint, making them too expensive to integrate at scale (SRAM). Currently, AI computations almost exclusively rely on the power-hungry DRAM. As the energy consumption of AI continues to grow exponentially, the semiconductor industry is urgently seeking alternative memory solutions.

Johnny Hilbrant Partridge never worked an hour on Wall Street, but you’d never guess that by looking at him. Nearly every day, Partridge takes to YouTube to channel his inner finance bro as P. E. Guy, a puffer-vested private equity putz who brags about his million-dollar deals, Aspen manse and private plane. Partridge, who once taught fitness classes in Boston, debuted the character on social media last year, which boosted his following beyond Barry’s and SoulCycle devotees. Today, he has 400,000-plus Instagram followers, up from 7,000 about 18 months ago.

News|Articles|October 24, 2026 Baseline and on-treatment circulating tumor DNA (ctDNA) features, including TP53 mutations and methylation-based tumor fraction, were associated with early progression or prolonged progression-free survival (PFS) with first-line lorlatinib (Lorbrena) in patients with ALK-positive advanced non–small cell lung cancer (NSCLC), in exploratory analyses of the phase 3 CROWN trial (NCT03052608) presented at the 2026 European Society for Medical Oncology (ESMO) Congress.1Compared with long-term responders, who were progression free at 84 months (n = 30), early progressors, who had a PFS event within 12 months (n = 22), had a higher median number of altered genes at baseline (10 vs 6), a higher median blood-based tumor mutation burden (7.7 vs 5.1), and more frequent TP53 mutations (50% vs 17%). In the lorlatinib arm, the 7-year PFS rate was 65.0% (95% CI, 54.5%-77.4%) in patients with TP53 wild-type disease (n = 73) vs 40.8% (95% CI, 27.3%-61.1%) in those with TP53-mutated disease (n = 43; HR, 0.48; 95% CI, 0.268-0.857); median PFS was not reached (NR) vs 51.6 months (95% CI, 16.4-NR), respectively.

CML treatment has transformed long-term survival, allowing many patients receiving effective TKI therapy to achieve a life expectancy approaching that of the general population. Molecular response milestones guide personalized treatment decisions, helping clinicians assess treatment effectiveness, recognize inadequate responses, and adjust therapy when necessary.